Anti-PD-L1-based therapies may improve some outcomes over sunitinib in patients with metastatic renal cell carcinoma, a meta-analysis suggests.
Results of a global survey highlight areas for improvement in the care of patients with renal cell carcinoma.
Cancer patients with type 2 diabetes may have worse survival outcomes on immune checkpoint inhibitor therapy, a new study suggests.
Adding cabozantinib to first-line treatment with ipilimumab plus nivolumab improved progression-free survival in patients with advanced, intermediate- or poor-risk renal cell carcinoma.
Perioperative outcomes of cytoreductive nephrectomy for metastatic renal cell carcinoma improved from 2005 to 2019.
Blood type may impact immunotherapy outcomes in patients with metastatic RCC, a study suggests.
Percutaneous cryoablation of localized T1a RCC provides long-term oncologic control with a low rate of complications, according to researchers.
ALLO-316 has shown activity in a phase 1 study of patients with heavily pretreated, advanced clear cell renal cell carcinoma.
Combination treatment with belzutifan and cabozantinib has demonstrated antitumor activity in previously treated, advanced clear cell renal cell carcinoma.
Avelumab plus cabozantinib has shown preliminary clinical activity and an acceptable safety profile in metastatic clear cell RCC, according to researchers.
Researchers have identified 15 novel loci associated with cancer and discovered genetic correlations across different cancer types.
The conversion from accelerated approval to regular approval was based on data from the KEYNOTE-158 trial, the KEYNOTE-164 trial, and the KEYNOTE-051 trial.
Findings may inform treatment decisions after nephrectomy with positive surgical margins.
Change in subcutaneous fat after initiation of immune checkpoint inhibitors may distinguish which patients will and will not respond to therapy.
Partial vs radical cytoreductive nephrectomy for clear cell metastatic renal cell carcinoma was associated with a 54% decreased risk for other-cause mortality.
Lenvatinib plus pembrolizumab improved outcomes vs sunitinib in patients with advanced renal cell carcinoma.
Investigators concluded that pN1 RCC could be stratified into pN1 and pN2, with pN2 conferring a poor prognosis comparable to that of non-metastatic stage IV pN0 disease.
A new study suggests that fluoroquinolones — but not other antibiotics — may reduce the efficacy of certain ICIs in certain cancers.
Researchers have characterized common adverse reactions to combination lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma.
A novel imaging technique, 89Zr-DFO-girentuximab PET/CT, can accurately and noninvasively identify clear cell renal cell carcinoma, a study suggests.